Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 08 - 11 tags : Treatment save search
Xeris Pharmaceuticals Announces FDA Acceptance of its IND Application for XeriSol™ Levothyroxine (XP-8121) for the Treatment of Hypothyroidism
Published: 2021-08-11 (Crawled : 22:00) - biospace.com/
XERS | $1.79 -0.56% -0.56% 1.5M
|
Health Technology
|
| O: 0.43%
H: 1.29%
C: 1.29%
treatment fda fda acceptance application
Radiotherapy Market Size to Reach USD 7.65 Billion in 2027 | Increasing Global Incidence of Cancer, Rising Use of Radiotherapy in Combination with Other Treatment Approaches are Some Key Factors Driving Industry Demand, says Emergen Research
Published: 2021-08-11 (Crawled : 14:15) - prnewswire.com
VRAY | $0.025 -39.9% -61.87% 110M
|
Health Technology
|
| O: 0.0%
H: 0.67%
C: -4.88%
ARAY | News | $2.205 -1.12% -1.13% 460K
|
Health Technology
|
| O: -0.5%
H: 0.0%
C: -1.0%
treatment therapy cancer research iot merge
Plus Therapeutics to Present Data from Two Studies Supporting the Treatment of Leptomeningeal Metastases with Rhenium-186 Nanoliposome
Published: 2021-08-11 (Crawled : 14:15) - globenewswire.com
PSTV | $1.74 -0.57% -0.57% 28K
|
Health Technology
|
| O: 0.0%
H: 24.06%
C: 11.23%
treatment
AcQMap 8, Acutus Medical’s Innovative Suite of Software Upgrades, Receives FDA Clearance and CE MarkEnhanced Software Automatically Identifies Regions of Interest During the Treatment of Complex Atrial Arrhythmias
Published: 2021-08-11 (Crawled : 13:15) - biospace.com/
AFIB | $0.1635 -0.49% -0.49% 63K
|
Health Technology
|
| O: 0.63%
H: 1.04%
C: -0.41%
fda clearance treatment fda software ce mark trial clearance
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-184 in the Treatment of Pancreatic Cancer
Published: 2021-08-11 (Crawled : 13:00) - biospace.com/
LTRN | $6.0 0.0% 160K
|
Health Technology
|
| O: 10.01%
H: 0.41%
C: -11.34%
treatment fda cancer drug pancreatic pancreas granted grant designation pharma
Akouos Announces European Commission Designation of AK-OTOF for the Treatment of Otoferlin Gene-Mediated Hearing Loss as an Orphan Drug
Published: 2021-08-11 (Crawled : 12:00) - biospace.com/
AKUS | $13.29 1.07% 3.46%
|
Health Technology
|
| O: 3.16%
H: 0.0%
C: -5.9%
media treatment europe drug hearing loss designation
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.